Ozempic vs Mounjaro: Head-to-Head Diabetes Comparison

Head-to-head trials (SURPASS-2) showed Mounjaro producing greater A1C reductions and more weight loss than Ozempic at comparable doses. However, both are highly effective GLP-1 medications, and the best choice depends on your individual health profile, insurance coverage, and provider recommendation.

Mounjaro's dual GIP/GLP-1 receptor activation is believed to enhance metabolic effects beyond what GLP-1 alone achieves. The GIP component appears to improve fat metabolism and insulin sensitivity through additional pathways, resulting in 15-21% average weight loss versus 10-15% with Ozempic.

Yes, switching is common and can be done under medical supervision. Your provider will typically restart at a lower Mounjaro dose (2.5 mg) regardless of your current Ozempic dose, then titrate up as tolerated. Discuss timing and dose transitions during your Weight Method consultation.

The side effect profiles are similar — both commonly cause nausea, vomiting, diarrhea, and decreased appetite, especially during dose escalation. Some studies suggest Mounjaro may have slightly lower rates of nausea at equivalent efficacy doses, but individual responses vary significantly.

Retail prices for both exceed $1,000/month without insurance. Through Weight Method, compounded semaglutide (Ozempic's active ingredient) is $297/mo and compounded tirzepatide (Mounjaro's active ingredient) is $349/mo, both including provider consultation and ongoing medical support.